Bicara names Ryan Cohlhepp CEO effective Jan 2027; Q2 net loss widens to $55.4M

Bicara Therapeutics Inc.

Net loss $55.4M in Q2 2026 vs $27.4M in Q2 2025; R&D expense $45.8M (up from $24.8M).
Cash, equivalents, marketable securities $497.3M at June 30, 2026; funded into 1H 2029.
Ryan Cohlhepp (President/COO) to become CEO Jan 1, 2027; Claire Mazumdar moves to Vice Chair.
Tanya Green promoted to COO, Jenn Larson appointed CFO effective Aug 12, 2026; other C-suite changes.
FORTIFI-HN01 pivotal trial substantially enrolled by year-end; interim topline mid-2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.